Features | Partner Sites | Information | LinkXpress
Sign In
TERARECON, INC.
SCHILLER AG
AMPRONIX

MRI T1 Mapping Technique Diagnoses Genetic Disorder That Attacks the Heart, Brain, and Nerves

By Medimaging International staff writers
Posted on 16 Oct 2013
A genetic disorder that attacks multiple organs and typically causes fatal heart complications can be detected using a new magnetic resonance imaging (MRI) technique. This new diagnostic application has resulted in updated clinical guidelines for the diagnosis and treatment of Fabry disease in Canada.

The University of Alberta’s (Edmonton, AB, Canada) Faculty of Medicine & Dentistry researchers Drs. Gavin Oudit and Richard Thompson worked with Faculty colleagues Drs. Kelvin Chow and Alicia Chan on the discovery, as well as Dr. Aneal Khan from the University of Calgary (Alberta, Canada). The findings were published online before August 6, 2013, in the journal, Circulation-Cardiovascular Imaging, and involved 31 Alberta patients who have the disease.

Dr. Thompson and trainee Dr. Chow developed the MRI technique known as T1 mapping, which can identify heart damage and changes at early stages, earlier than regular MRI scans or ultrasound. When this type of MRI technology is used on patients with Fabry disease, the scans can detect both the disease and the degree of damage to the heart. The T1 mapping technology developed by the group can be easily programmed onto MRI scans worldwide.

“This test can uniquely identify Fabry disease by detecting microscopic changes in the heart muscle structure that are not visible on regular images,” said Dr. Thompson, who works in the department of biomedical engineering. “Fabry disease can look like other diseases if you only look at the whole heart structure or function, but this T1 mapping test, that can detect the tiniest changes in the heart, could identify all the patients with Fabry disease. It is very likely that this technique will become a key part in clinical examination of patients with Fabry disease. This finding will advance the clinical care of these patients around the world. The implications will be widespread. Heart disease is the number one cause of death for patients with Fabry disease. The earlier the disease can be pinpointed, the sooner treatment can start. The treatment for the disease halts the condition and prevents serious damage to the heart.”

Fabry disease is a genetic metabolic disorder that destroys the enzyme involved in fat metabolism. This enzyme dissolves fat so without it, those with the disease accumulate lethal fat deposits in their heart, kidneys, and brain. The condition affects 1 in 1,500 to 3,000 people, but was first believed to be a rare disease. Various countries now screen newborns for the condition that costs USD 200,000 yearly to treat through monthly infusions called enzyme replacement therapy. Symptoms of the disease include heart failure, blackouts, thickened walls of the heart, exercise intolerance, fluid accumulation in the legs, inability to lie down, strokes, tingling in the hands and feet, and changes in skin pigmentation.

The T1 mapping test can both detect the disease and evaluate damage to the heart. Dr. Oudit reported that this new MRI technique “is a wonderful story of collaboration--of patients, clinicians, scientists, and industry working together to find a new diagnostic tool.”

“As an organization, we are excited to be part of these developments through the research from the University of Alberta,” said Mauro Chies, acting vice-president of clinical supports for Alberta Health Services. “This is a significant advancement in the detection of disease in a noninvasive environment for our patients. We hope to be able to advance these sequences on our MRIs in the near future, and look for ways to use it to evaluate and detect other disease conditions.”

The project was done in collaboration with Siemens Canada, Ltd. and Siemens Healthcare USA, Inc. (Malvern, PA, USA).

Related Links:

University of Alberta
University of Calgary
Siemens Healthcare




RTI ELECTRONICS AB
RADCAL
SuperSonic Imagine

Channels

Ultrasound

view channel
Image: Siemens Healthcare has launched the HELX Evolution, the newest iteration of its Acuson S range of ultrasound imaging systems (Photo courtesy of Siemens Healthcare).

Ultrasound Imaging System Enhancements Include High Definition Transducers, Sophisticated Elastography, and Tissue Strain Analysis

New features designed for a range of ultrasound systems include enhanced image quality with a large 21.5-inch liquid crystal diode (LCD) monitor, high definition (HD) transducers, optimized contrast agent... Read more

Nuclear medicine

view channel
Image: Sagittal section of brain PET image at four hours after 64CuCl2 injection with disulfiram or D-penicillamine in MD model mice (Photo courtesy of the RIKEN Center for Life Science Technologies).

PET Imaging Used to Assess Effectiveness of Menkes Disease Treatments

Japanese scientists are using positron emission tomography (PET) imaging to visualize the distribution of copper in the body using lab mice. Copper distribution is deregulated in a genetic disorder called... Read more

General/Advanced Imaging

view channel

Secondary Light Emission Generated by Plasmonic Nanostructures May Improve Medical Imaging Technology

New clues into light emission at different wavelengths generated by elements known plasmonic nanostructures may help to improve medical imaging technology. A plasmon is a quantum of plasma oscillation. The plasmon is a quasiparticle resulting from the quantization of plasma oscillations just as photons, and phonons are... Read more

Imaging IT

view channel

Software Designed for the Assessment of Orthopedic Implant Fixation and Bone Segment Motion

Model-based roentgen stereophotogrammetric analysis (MBRSA) software has been developed for evaluation of orthopedic implant fixation and bone segment motion. The software is the first to measure the in vivo three-dimensional (3D) position and/or relative motion of metal implants, markers beads, and/or bone segments in... Read more

Industry News

view channel

Collaboration Expands Capacity for Proton Therapy Clinical Research and Patient Treatments

Varian Medical Systems (Palo Alto, CA, USA) and the Paul Scherrer Institute (PSI; Villigen PSI, Switzerland) are extending an existing collaboration in the field of proton therapy to offer patients more accurate cancer treatments using intensity-modulated proton therapy (IMPT). Under the agreement, Varian will also... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.